Skip to main content
Caplight Logo









Deepson Bio

Deepson Bio

Private
South KoreaHealthcare & Life Scienceshttps://deepsonbio.com/

Last Round

Pre A

Apr 14, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Deepson Bio operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a Pre A round in April 2025.

Deepson Bio is a medical technology company that develops therapeutic ultrasound devices intended to treat severe diseases and disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Deepson Bio Comparables

Compare Deepson Bio with similar companies based on industry and business-model similarity.

Deepson Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neurosona
86%
Ceretas
84%
Zhongke Green Valley (Shenzhen) Medical Technology Co., Ltd.
83%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Deepson Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre AApr 14, 2025
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open job postings increased to 1 role, representing 33% of headcount.

  • Jun 21, 2026

    Monthly visitors increased 60% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

Deepson Bio Filings

Explore SEC and related filing metadata, where available.

Deepson Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Deepson Bio's valuation, stock price, and market status.

Is Deepson Bio a public or private company?

Deepson Bio is a private company.

What is the current stock price of Deepson Bio?

Deepson Bio is a private company, so its shares have no public market price. Caplight tracks Deepson Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Deepson Bio worth (valuation)?

Valuation information for Deepson Bio is not publicly available.

Can I buy Deepson Bio stock?

Deepson Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Deepson Bio's last funding round?

Deepson Bio's most recent funding round was Pre A on April 14, 2025.

Who are the main investors in Deepson Bio?

Investor information for Deepson Bio is not publicly disclosed.

Will Deepson Bio IPO soon?

No public IPO plans have been announced for Deepson Bio.

How can I track Deepson Bio secondary market activity?

Caplight tracks bids, offers, and trades in Deepson Bio's shares on secondary markets.

Firmographic Details

HeadquartersSouth Korea
Employee Range3
Year Founded2018
Last FundingApr 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?